摘要
目的探讨德谷胰岛素联合利拉鲁肽对2型糖尿病(T2DM)患者血糖波动及氧化应激指标的影响。方法选取2023年4月至2024年3月该院收治的146例T2DM患者作为研究对象,采用随机数字表法分为观察组和对照组,每组73例。对照组给予德谷胰岛素治疗,观察组在对照组基础上联合利拉鲁肽治疗。比较2组的治疗有效率、血糖波动指标[血糖水平的标准差(SDBG)、平均血糖波动幅度(MAGE)、日间血糖平均绝对值(MODD)、24 h血糖波动次数(NGE)、糖化血红蛋白(HbA1c)]、血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)]、血脂[甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)]、氧化应激指标[脂质过氧化氢(LHP)、丙二醛(MDA)、总抗氧化能力(T-AOC)、谷胱甘肽过氧化物酶(GSH-Px)]水平和不良反应发生情况。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,2组患者SDBG、MAGE、MODD、NGE、HbA1c、TG、FPG、LDL-C、2 h PG、TC、LHP、MDA水平均降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组患者T-AOC、GSH-Px水平升高,且观察组高于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率为13.70%,对照组不良反应发生率为10.96%,2组比较,差异无统计学意义(P>0.05)。结论德谷胰岛素联合利拉鲁肽能显著提高T2DM患者临床疗效,减少血糖波动,降低血糖、血脂及LHP、MDA水平,具有良好的安全性。
Objective To investigate the effects of insulin degludec combined with liraglutide on glycemic variability and oxidative stress markers in patients with type 2 diabetes mellitus(T2DM).Methods A total of 146 patients with T2DM who were treated at this hospital from April 2023 to March 2024 were enrolled and randomly assigned into the observation group and control group using a random number table,with 73 patients in each group.The control group received insulin degludec treatment,while the observation group received liraglutide in addition to insulin degludec.Treatment efficacy,glycemic variability indicators[standard deviation of blood glucose(SDBG),mean amplitude of glycemic excursions(MAGE),mean of daily differences(MODD),number of glycemic excursions over 24 h(NGE)and glycated hemoglobin(HbA1c)],blood glucose[fasting plasma glucose(FPG)and 2 h postprandial glucose(2 h PG)],lipid profiles[triglycerides(TG),low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)],oxidative stress markers[lipid hydroperoxide(LHP),malondialdehyde(MDA),total antioxidant capacity(T-AOC)and glutathione peroxidase(GSH-Px)]levels,as well as adverse events were compared between the two groups.Results The overall treatment efficacy was significantly higher in the observation group compared with the control group(P<0.05).After treatment,levels of SDBG,MAGE,MODD,NGE,HbA1c,TG,FPG,LDL-C,2 h PG,TC,LHP and MDA were significantly reduced in both groups(P<0.05),and which in the observation group were significantly lower than those in the control group(P<0.05).Levels of T-AOC and GSH-Px significantly increased after treatment in both groups(P<0.05),and which in the observation group were significantly higher compared with the control group(P<0.05).The incidence of adverse events was 13.70%in the observation group and 10.96%in the control group,with no statistically significant difference between the two groups(P>0.05).Conclusion The combination of insulin degludec and liraglutide can significantly improve clinical outcomes in patients with type 2 diabetes mellitus,effectively reduce glycemic variability,lower blood glucose,lipid levels,lipid hydroperoxide and malondialdehyde,and demonstrates good safety.
作者
吕露
柯婧
李靓
王伟
LYU Lu;KE Jing;LI Liang;WANG Wei(Department of Pharmacy,Ezhou Central Hospital,Ezhou,Hubei 436000,China;Department of Endocrinology,Ezhou Central Hospital,Ezhou,Hubei 436000,China;Department of Nephrology,Ezhou Central Hospital,Ezhou,Hubei 436000,China)
出处
《检验医学与临床》
2025年第11期1508-1512,共5页
Laboratory Medicine and Clinic
基金
湖北省自然科学基金项目(2022CFB599)。
关键词
德谷胰岛素
利拉鲁肽
2型糖尿病
血糖
脂质过氧化氢
insulin degludec
liraglutide
type 2 diabetes mellitus
blood glucose
lipid hydroperoxide
作者简介
吕露,女,主管药师,主要从事临床药学研究;通信作者:王伟,E-mail:382199095@qq.com。
